The promise of immuno-PET in radioimmunotherapy

Journal of Nuclear Medicine

Volumn 46, Issue 1 SUPPL., 2005, Pages

  Verel, Iris ^a   Visser, Gerard W M ^a   Van Dongen, Guus A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Immuno PET; Monoclonal antibodies; Oncology; Positron emitters; Radioimmunotherapy

Indexed keywords

BROMINE 76; CARCINOEMBRYONIC ANTIGEN; COPPER 64; COPPER 67; GALLIUM 67; IBRITUMOMAB TIUXETAN; IODINE 123; IODINE 124; RADIOISOTOPE; RHENIUM 186; RHENIUM 188; STRONTIUM 89; TECHNETIUM 99M; TOSITUMOMAB I 131; YTTRIUM 90; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT;

CANCER THERAPY; DOSIMETRY; DRUG CONJUGATION; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RADIOACTIVITY; RADIOIMMUNOASSAY; RADIOIMMUNOTHERAPY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOLID TUMOR; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; METHODOLOGY; NEOPLASM; PRACTICE GUIDELINE; PROGNOSIS; SCINTISCANNING; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; POSITRON-EMISSION TOMOGRAPHY; PRACTICE GUIDELINES; PROGNOSIS; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 14844355681     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med. 2003;44:465- 474.
2. Wahl RL. The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I-131 tositumomab. Semin Oncol. 2003;30:31-38.
3. Geworski L, Knoop BO, de Cabrejas ML, Knapp WH, Munz DL. Recovery correction for quantitation in emission tomography: a feasibility study. Eur J Nucl Med. 2000;27:161-169.
4. 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. J Nucl Med. 2003;44:1663-1670.
5. Phelps ME, Hoffman EJ, Mullani NA, Ter-Pogossian MM. Application of annihilation coincidence detection to transaxial reconstruction tomography. J Nucl Med. 1975;16:210-224.
6. Melcher CL. Scintillation crystals for PET. J Nucl Med. 2000;41:1051-1055.
7. Humm JL, Rosenfeld A, Del Guerra A. From PET detectors to PET scanners. Eur J Nucl Med Mol Imaging. 2003;30:1574-1597.
8. Czernin J, Schelbert H. PET/CT imaging: facts, opinions, hopes, and questions. J Nucl Med. 2004;45(suppl):1S-3S.
9. 94mTc for positron emission tomography studies. Nucl Med Biol. 2000;27:323-328.
10. Smith MF, Daube-Witherspoon ME, Plascjak PS, et al. Device-dependent activity estimation and decay correction of radionuclide mixtures with application to Tc-94m PET studies. Med Phys. 2001;28:36-45.
11. Pagani M, Stone-Elander S, Larsson SA. Alternative positron emission tomography with non-conventional positron emitters: effects of their physical properties on image quality and potential clinical applications. Eur J Nucl Med. 1997;24:1301-1327.
12. Glaser M, Luthra SK, Brady F. Applications of positron-emitting halogens in PET oncology. Int J Oncol. 2003;22:253-267.
13. 64Cu using a biomedical cyclotron. Nucl Med Biol. 1997;24:35-43.
14. 86Y for nuclear medical applications. Appl Radiat Isot. 1993;44:677-681.
15. 111In labeled herceptin. Nucl Med Biol. 2002;29:599-606.
16. Walrand S, Jamar F, Mathieu I, et al. Quantitation in PET using isotopes emitting prompt single gammas: application to yttrium-86. Eur J Nucl Med. 2003;30:354-361.
17. 76Br with 2D and 3D PET. Phys Med Biol. 2002;47:3519-3534.
18. 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003;44:1271-1281.
19. Pentlow KS, Graham MC, Lambrecht RM, et al. Quantitative imaging of iodine-124 with PET. J Nucl Med. 1996;37:1557-1562.
20. 124I. Appl Radiat Isot. 2002;56:673-679.
21. Sowby FD, ed. Radionuclide Transformations: Energy and Intensity of Emissions. International Commission on Radiological Protection Publication 38. Vol. 11-13. Oxford, UK: Pergamon Press; 1983:14, 74, 90, 144, 202, 218, 249, 444.
22. Kinsey RR, ed. The NuDat Program for Nuclear Data on the Web. Version 2.5. Available at: http://www.nndc.bnl.gov/nndc/nudat/. Accessed September 1, 2004.
23. 2 fragment in a subcutaneous xenograft model. Cancer Res. 1992;52:5054-5060.
24. 125I-labeled anti-Tac disulfide-stabilized Fv fragments in nude mice with interleukin 2 alpha receptor-positive tumor xenografts. Cancer Res. 1995;55:5323-5329.
25. Griffiths GL, Goldenberg DM, Roesch F, Hansen HJ. Radiolabeling of an anti-carcinoembryonic antigen antibody Fab-′ fragment (CEA-scan) with the positron-emitting radionuclide Tc-94m. Clin Cancer Res. 1999;5:3001s-3003s.
26. Klivényi G, Schuhmacher J, Patzelt E, et al. Gallium-68 chelate imaging of human colon carcinoma xenografts pretargeted with bispecific anti-CD44V6/anti-gallium chelate antibodies. J Nucl Med. 1998;39:1769-1776.
27. Schuhmacher J, Kaul S, Klivényi G, et al. Immunoscintigraphy with PET: Ga-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies. Cancer Res. 2001;61:3712-3717.
28. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging of the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol. 2004;22:701-706.
29. Philpott GW, Schwarz SW, Anderson CJ, et al. RadioimmunoPET: detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. J Nucl Med. 1995;36:1818-1824.
30. Wu AM, Yazaki PJ, Tsai S, et al. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci USA. 2000;97:8495-8500.
31. 64Cu for tumor imaging and therapy. J Nucl Med. 2003;44:1284-1292.
32. 111In radiolabels. J Nucl Med. 2001;42:1281-1287.
33. Lövqvist A, Sundin A, Alström H, Carlsson J, Lundqvist H. Pharmacokinetics and experimental PET imaging of a bromine-76-labeled monoclonal anti-CEA antibody. J Nucl Med. 1997;38:395-401.
34. 124I-labelled monoclonal antibody H17E2 in a human tumour xenograft model. A prelude to positron emission tomography (PET). Br J Cancer 1990;10(suppl):89-91.
35. Westera G, Reist HW, Buchegger F, et al. Radioimmuno positron emission tomography with monoclonal antibodies: a new approach to quantifying in vivo tumour concentration and biodistribution for radioimmunotherapy. Nucl Med Commun. 1991;12:429-437.
36. Larson SM, Pentlow KS, Volkow ND, et al. PET scanning of iodine-124-3F8 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. J Nucl Med. 1992;33:2020-2023.
37. 124I in patients with breast cancer. Int J Cancer. 1991;47:344-347.
38. 124I-CDR-grafted humanized A33 monoclonal antibody. J Nucl Med. 2001;42:764-769.
39. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med. 2003;44:1962-1969.
40. 131I-radioimmunotherapy. Eur J Nucl Med Mol Imaging. July 31, 2004. [Epub ahead of print.]